Retrophin Reports Fourth Quarter and Full Year 2017 Financial Results

Retrophin (NASDAQ:RTRX) today reported its fourth quarter and full year 2017 financial results and provided a corporate update.

As quoted in the press release:

“2017 was an important year of execution for Retrophin, marked by meaningful progress across our clinical development efforts, as well as continued strong commercial and operational performance,” said Stephen Aselage, chief executive officer of Retrophin. “We are also very pleased with our recent communications with the FDA regarding our sparsentan program for FSGS, for which we have reached alignment to pursue Subpart H accelerated approval with our planned Phase 3 trial. With four programs advancing in the clinic, 2018 is poised to be an exceptional year during which we expect to drive significant value for patients and shareholders alike.”

Click here to read the full press release.